{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:34:01Z","timestamp":1793694841244,"version":"4.5.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clinthera.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:51:02Z","timestamp":1773982262000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antipsychotic Treatment Pathways, Real-World Adherence, Healthcare Resource Utilization, and Healthcare Costs Among Patients With Schizophrenia Treated With Once-Monthly, Once-Every-Three-Months, and Once-Every-Six-Months Paliperidone Palmitate in the United States"],"prefix":"10.1016","volume":"48","author":[{"given":"Laura","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Voegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Yokoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.02.006_bib0001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jphs.12027","article-title":"Estimating the direct and indirect costs for community-dwelling patients with schizophrenia","volume":"4","author":"Desai","year":"2013","journal-title":"J Pharm Health Serv Res"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0002","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.biopsych.2005.04.034","article-title":"The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)","volume":"58","author":"Kessler","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0003","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1017\/S0033291706008191","article-title":"Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach","volume":"36","author":"Wu","year":"2006","journal-title":"Psychol Med"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0004","unstructured":"National Alliance on Mental Illness. Schizophrenia. https:\/\/www.nami.org\/about-mental-illness\/mental-health-conditions\/schizophrenia\/ Accessed June 13, 2025."},{"key":"10.1016\/j.clinthera.2026.02.006_bib0005","series-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia","author":"Keepers","year":"2021"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0006","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","article-title":"Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis","volume":"35","author":"Lin","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0007","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.clinthera.2017.08.008","article-title":"Treatment patterns, health care resource utilization, and spending in medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics","volume":"39","author":"Pilon","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0008","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/03007995.2021.1882412","article-title":"Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate","volume":"37","author":"Lin","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0009","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/03007995.2018.1558195","article-title":"The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia","volume":"35","author":"El Khoury","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0010","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s12325-024-03075-6","article-title":"Real-world effectiveness of long-acting injectable and oral antipsychotic agents in US Medicare patients with schizophrenia","volume":"42","author":"Li","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/03007995.2018.1560220","article-title":"Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans","volume":"35","author":"Emond","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0012","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clinthera.2021.01.011","article-title":"Antipsychotic adherence, resource use, and costs before and after the initiation of once-monthly paliperidone palmitate therapy among medicaid beneficiaries with prior schizophrenia relapse","volume":"43","author":"Zhdanava","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0013","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/03007995.2021.1882977","article-title":"Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study","volume":"37","author":"Patel","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0014","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.2147\/PPA.S322880","article-title":"Relapse and treatment adherence in patients with schizophrenia switching from paliperidone palmitate once-monthly to three-monthly formulation: a retrospective health claims database analysis","volume":"15","author":"Li","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0015","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s12325-021-01626-9","article-title":"The impact of once-monthly paliperidone palmitate on healthcare utilization among patients with schizophrenia treated in an integrated healthcare system: a retrospective mirror-image study","volume":"38","author":"Mahabaleshwarkar","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0016","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1007\/s12325-019-01039-9","article-title":"Health outcomes among patients diagnosed with schizophrenia in the US veterans health administration population who transitioned from once-monthly to once-every-3-month paliperidone palmitate: an observational retrospective analysis","volume":"36","author":"Patel","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0017","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/13696998.2019.1615927","article-title":"Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia","volume":"22","author":"Song","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0018","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/cer-2018-0003","article-title":"Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population","volume":"7","author":"Joshi","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0019","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.clinthera.2018.07.011","article-title":"Health care resource utilization and costs associated with transitioning to 3-month paliperidone palmitate among US veterans","volume":"40","author":"DerSarkissian","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0020","unstructured":"Johnson & Johnson. Janssen announces U.S. FDA approval of INVEGA HAFYERA\u2122 (6-month paliperidone palmitate), first and only twice-yearly treatment for adults with schizophrenia. https:\/\/www.jnj.com\/media-center\/press-releases\/janssen-announces-u-s-fda-approval-of-invega-hafyera-6-month-paliperidone-palmitate-first-and-only-twice-yearly-treatment-for-adults-with-schizophrenia Accessed June 13, 2025."},{"key":"10.1016\/j.clinthera.2026.02.006_bib0021","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ijnp\/pyab071","article-title":"A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia","volume":"25","author":"Najarian","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0022","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ijnp\/pyad028","article-title":"Long-term efficacy and safety of paliperidone 6-month formulation: an open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia","volume":"26","author":"Najarian","year":"2023","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0023","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1186\/s12913-021-07196-4","article-title":"Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review","volume":"21","author":"Medlinskiene","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0024","unstructured":"US Food and Drug Administration. INVEGA HAFYERA\u00ae (paliperidone palmitate) extended-release injectable suspension, for gluteal intramuscular use. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INVEGA+HAFYERA-pi.pdf Accessed January 7, 2026."},{"key":"10.1016\/j.clinthera.2026.02.006_bib0025","unstructured":"Komodo Health Solutions. Imputing allowed amounts: Development and validation of an encounter-level allowed amount imputation model. https:\/\/www.komodohealth.com\/hubfs\/2023\/Komodo_Imputing_Allowed_Amounts_White_Paper.pdf Accessed January 7, 2026."},{"key":"10.1016\/j.clinthera.2026.02.006_bib0026","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/NDT.S395383","article-title":"The effect of longer dosing intervals for long-acting injectable antipsychotics on outcomes in schizophrenia","volume":"19","author":"Milz","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0027","doi-asserted-by":"crossref","first-page":"sgac013","DOI":"10.1093\/schizbullopen\/sgac013","article-title":"Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary: an update","volume":"3","author":"Takacs","year":"2022","journal-title":"Schizophr Bull Open"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.695672","article-title":"Associations between relapses and psychosocial outcomes in patients with schizophrenia in real-world settings in the United States","volume":"12","author":"Lin","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0029","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12888-022-04022-x","article-title":"Unemployment, homelessness, and other societal outcomes in patients with schizophrenia: a real-world retrospective cohort study of the United States Veterans Health Administration database: Societal burden of schizophrenia among US veterans","volume":"22","author":"Lin","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.euroneuro.2022.11.011","article-title":"Relapse, cognitive reserve, and their relationship with cognition in first episode schizophrenia: a 3-year follow-up study","volume":"67","author":"Sanchez-Torres","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0031","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2147\/NDT.S400342","article-title":"Efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month long-acting injectable in European patients with schizophrenia: a post hoc analysis of a global phase-3 double-blind randomized non-inferiority study","volume":"19","author":"Giron-Hernandez","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1540213","article-title":"Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y)","volume":"16","author":"Manchado Perero","year":"2025","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyad067","article-title":"Relapse rates with paliperidone palmitate in adult patients with schizophrenia: results for the 6-month formulation from an open-label extension study compared to real-world data for the 1-month and 3-month formulations","volume":"27","author":"Turkoz","year":"2024","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231200258","article-title":"Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia","volume":"13","author":"Turkoz","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0035","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1185\/03007995.2015.1050365","article-title":"Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics","volume":"31","author":"Benson","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0036","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2147\/NDT.S56107","article-title":"Strategies to improve medication adherence in patients with schizophrenia: the role of support services","volume":"11","author":"El-Mallakh","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0037","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1017\/S1092852924000476","article-title":"Comparing two transitioning strategies to paliperidone palmitate once-every-6-months","volume":"29","author":"Correll","year":"2024","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0038","first-page":"161","article-title":"Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate","volume":"29","author":"Morrison","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0039","first-page":"303","article-title":"Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans","volume":"29","author":"Phelps","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0040","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14458","article-title":"The economic burden of schizophrenia in the United States","volume":"83","author":"Kadakia","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0041","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1176\/appi.ps.20230142","article-title":"Out-of-pocket costs for long-acting injectable and oral antipsychotics among medicare patients with schizophrenia","volume":"75","author":"Doshi","year":"2024","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34016","article-title":"Racial and ethnic disparities in long-acting injectable antipsychotic use in a national sample of Medicare beneficiaries with schizophrenia","volume":"6","author":"Li","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0043","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/amhs.amhs_55_21","article-title":"Strategies for promoting treatment adherence in schizophrenia","volume":"10","author":"Pai","year":"2022","journal-title":"Arch Med Health Sci"},{"key":"10.1016\/j.clinthera.2026.02.006_bib0044","doi-asserted-by":"crossref","first-page":"222","DOI":"10.36469\/jheor.2025.137909","article-title":"Open access to antipsychotics in state Medicaid programs: effect on healthcare resource utilization and costs among patients with serious mental illness","volume":"12","author":"Patel","year":"2025","journal-title":"J Health Econ Outcomes Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:22:11Z","timestamp":1777490531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0149291826000408"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.02.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic Treatment Pathways, Real-World Adherence, Healthcare Resource Utilization, and Healthcare Costs Among Patients With Schizophrenia Treated With Once-Monthly, Once-Every-Three-Months, and Once-Every-Six-Months Paliperidone Palmitate in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}